Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947581034> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2947581034 abstract "e15645 Background: Hepatocellular carcinoma (HCC) is the 4th leading cause of global cancer deaths. In North America, HCC is most commonly caused by Hepatitis C virus (HCV). Direct acting antivirals (DAAs) have dramatically increased sustained virologic response (SVR) rates for HCV. Studies of DAAs in early stage HCC have had conflicting results on HCC outcomes. A small Asian study of 58 advanced HCC patients treated with sorafenib demonstrated SVR improved survival, but whether the same effect occurs in North American patients is unknown. Methods: Inclusion criteria for this retrospective study were: biopsy or clinically proven advanced incurable HCC, sorafenib treatment at Princess Margaret Cancer Centre between January 1 2008-June 30 2018 and a history of HCV. Survival was analyzed using the Kaplan Meier method and a cox proportional hazards model was fit to determine the effect of SVR on OS. Results: 93 patients were included with a median duration of sorafenib therapy of 3 months. 89% were ECOG 0-1 and 96% were BCLC-C (See table 1). Of those receiving antivirals, 95% were given before sorafenib. Overall, SVR was achieved in 23 (50%) patients. Median OS of patients achieving SVR vs not in SVR was 10.3 vs 8.9 months respectively (HR 0.67, 95% CI 0.36-1.24, p = 0.20). Median PFS was 6.4 vs 5.0 months in patients with or without SVR (HR 0.66, 95% CI 0.39-1.13, p = 0.13). There was no significant difference between mean dose of sorafenib or discontinuation due to toxicity in patients by SVR status. Conclusions: Antiviral therapy with SVR lead to a non-statistically significant improvement in OS in patients with Child-Pugh A-B liver disease, advanced HCC treated with sorafenib and HCV. These results should be validated in larger data-sets. [Table: see text]" @default.
- W2947581034 created "2019-06-07" @default.
- W2947581034 creator A5004471930 @default.
- W2947581034 creator A5028677586 @default.
- W2947581034 creator A5028872384 @default.
- W2947581034 creator A5047300992 @default.
- W2947581034 creator A5068644454 @default.
- W2947581034 date "2019-05-20" @default.
- W2947581034 modified "2023-09-24" @default.
- W2947581034 title "Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib." @default.
- W2947581034 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15645" @default.
- W2947581034 hasPublicationYear "2019" @default.
- W2947581034 type Work @default.
- W2947581034 sameAs 2947581034 @default.
- W2947581034 citedByCount "0" @default.
- W2947581034 crossrefType "journal-article" @default.
- W2947581034 hasAuthorship W2947581034A5004471930 @default.
- W2947581034 hasAuthorship W2947581034A5028677586 @default.
- W2947581034 hasAuthorship W2947581034A5028872384 @default.
- W2947581034 hasAuthorship W2947581034A5047300992 @default.
- W2947581034 hasAuthorship W2947581034A5068644454 @default.
- W2947581034 hasConcept C126322002 @default.
- W2947581034 hasConcept C143998085 @default.
- W2947581034 hasConcept C159047783 @default.
- W2947581034 hasConcept C2522874641 @default.
- W2947581034 hasConcept C2776408679 @default.
- W2947581034 hasConcept C2778019345 @default.
- W2947581034 hasConcept C2778695046 @default.
- W2947581034 hasConcept C71924100 @default.
- W2947581034 hasConcept C90924648 @default.
- W2947581034 hasConceptScore W2947581034C126322002 @default.
- W2947581034 hasConceptScore W2947581034C143998085 @default.
- W2947581034 hasConceptScore W2947581034C159047783 @default.
- W2947581034 hasConceptScore W2947581034C2522874641 @default.
- W2947581034 hasConceptScore W2947581034C2776408679 @default.
- W2947581034 hasConceptScore W2947581034C2778019345 @default.
- W2947581034 hasConceptScore W2947581034C2778695046 @default.
- W2947581034 hasConceptScore W2947581034C71924100 @default.
- W2947581034 hasConceptScore W2947581034C90924648 @default.
- W2947581034 hasLocation W29475810341 @default.
- W2947581034 hasOpenAccess W2947581034 @default.
- W2947581034 hasPrimaryLocation W29475810341 @default.
- W2947581034 hasRelatedWork W1189701599 @default.
- W2947581034 hasRelatedWork W1974978678 @default.
- W2947581034 hasRelatedWork W2024477064 @default.
- W2947581034 hasRelatedWork W2049812177 @default.
- W2947581034 hasRelatedWork W2124101927 @default.
- W2947581034 hasRelatedWork W2267131559 @default.
- W2947581034 hasRelatedWork W2277323606 @default.
- W2947581034 hasRelatedWork W2589451799 @default.
- W2947581034 hasRelatedWork W2589754650 @default.
- W2947581034 hasRelatedWork W2594177569 @default.
- W2947581034 hasRelatedWork W2775769278 @default.
- W2947581034 hasRelatedWork W2779696142 @default.
- W2947581034 hasRelatedWork W2790951398 @default.
- W2947581034 hasRelatedWork W2799277806 @default.
- W2947581034 hasRelatedWork W2890390561 @default.
- W2947581034 hasRelatedWork W2892191661 @default.
- W2947581034 hasRelatedWork W2921138325 @default.
- W2947581034 hasRelatedWork W3139590395 @default.
- W2947581034 hasRelatedWork W3200375056 @default.
- W2947581034 hasRelatedWork W2587323145 @default.
- W2947581034 isParatext "false" @default.
- W2947581034 isRetracted "false" @default.
- W2947581034 magId "2947581034" @default.
- W2947581034 workType "article" @default.